The secretive startup is trying to “make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy,” according to its website. Good said it is developing an algorithm that will design proteins for cancer therapies.
Founder and CEO John Mulligan confirmed the $11 million round but declined to comment on what it means for the company when contacted by GeekWire.
Mulligan, who earned his doctorate in biology from Stanford University, previously worked as a consultant for Microsoft on a system for storing data on strands of DNA, according to his LinkedIn. He also founded Glycostasis, a company that designed a protein to regulate insulin levels, and co-founded Cambrian Genomics, which created a way to laser print DNA.
Good’s offices are in Seattle’s Fremont neighborhood, according to the filing. The company listed the following directors:
- John McKearn, managing director of life science venture capital firm RiverVest Venture Partners.
- Mitchell Mutz, an investment director at Roche Venture Fund, the investment arm of pharmaceutical giant Roche.
- Karl Handelsman, an investment director at Roche Venture Fund.
- Nicholas Walrod, managing director of Portland-based VC firm 3×5 Partners.